A new 123I-MIBG whole body scan scoring method—Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma-Reference-Cited by-同舟云学术

A new 123I-MIBG whole body scan scoring method—Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma

Published:1995-01 Issue:2 Volume:31 Page:256-261
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Ady N.,Zucker J.-M.,Asselain B.,Edeline V.,Bonnin F.,Michon J.,Gongora R.,Manil L.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference10 articles.

1. Visualization of human adrenal glands in vivo by scintillation scanning;Beierwaltes;JAMA,1971

2. Scintigraphie à la métaiodo-benzylguanidine: bilan d'une première année d'expérience;Baulieu;J Biophys Méd Nucl,1984

3. Total body scanning with 1311-metaiodobenzylguanidine for detection of neuroblastoma;Hoefnagel;Diagn Imag Clin Med,1985

4. Radionuclide diagnosis and therapy of neural crest: tumors using iodine-131 metaiodoben-zylguanidine;Hoefnagel;J Nucl Med,1987

5. Meta-iodo-benzyl-guanidine (MIBG) labeled with 123I-131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the international workshop of pediatric oncology;Feine,1987

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors;Pediatric Blood & Cancer;2024-01-08

2. Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the Children's Oncology Group;Pediatric Blood & Cancer;2023-05-18

3. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma;Cancer;2023-04-20

4. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results;Nature Medicine;2023-04-03

5. Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma;International Journal of Radiation Oncology*Biology*Physics;2023-04